Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma

Virchows Archiv

Volumn 464, Issue 4, 2014, Pages 463-471

  Hayashi, Akimasa ^a   Morikawa, Teppei ^a   Kawai, Taketo ^a   Kume, Haruki ^a   Ishikawa, Shumpei ^b   Homma, Yukio ^a   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Epigenetics; Histone methyltransferase; Prognostic biomarker; Renal pelvis; Ureter; Urothelial carcinoma

Indexed keywords

KI 67 ANTIGEN; TRANSCRIPTION FACTOR EZH2;

AGED; ARTICLE; CANCER PATIENT; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CARCINOMA IN SITU; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; NEPHROURETERECTOMY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; URINARY TRACT CARCINOMA;

AGED; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; LYMPHATIC METASTASIS; MALE; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS; UROTHELIUM;

EID: 84899079827     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-014-1541-6     Document Type: Article

References (47)

1. Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Bohle A, Van Rhijn BW, Kaasinen E, Palou J, Shariat SF (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63:1059-1071
2. Remzi M, Shariat S, Huebner W, Fajkovic H, Seitz C (2011) Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? Ther Adv Urol 3:69-80. doi: 10.1177/1756287211403349
3. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, Tanaka T, Masumori N, Sato N, Tsukamoto T (2013) Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch 462:101-107
4. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martinez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V (2012) Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 61:818-825. doi: 10.1016/j.eururo.2012.01.021
5. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF (2011) Prognostic factors for upper urinary tract urothelial carcinoma. Nat Rev Urol 8:440-447. doi: 10.1038/nrurol.2011.96
6. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100-114. doi: 10.1016/j.eururo.2012.02.030
7. Garraway LA, Lander ES (2013) Lessons from the cancer genome. Cell 153:17-37. doi: 10.1016/j.cell.2013.03.002
8. Shen H, Laird PW (2013) Interplay between the cancer genome and epigenome. Cell 153:38-55. doi: 10.1016/j.cell.2013.03.008
9. Sparmann A, van Lohuizen M (2006) Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6:846-856
10. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606-11611
11. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21-29
12. Grignon DJ (2009) The current classification of urothelial neoplasms. Mod Pathol 22(Suppl 2):S60-S69. doi: 10.1038/modpathol.2008.235
13. Morikawa T, Maeda D, Kume H, Homma Y, Fukayama M (2010) Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57:885-892
14. Raaphorst FM, van Kemenade FJ, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ (2000) Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol 164:1-4
15. Hinz S, Magheli A, Weikert S, Schulze W, Krause H, Schrader M, Miller K, Kempkensteffen C (2010) Deregulation of EZH2 expression in human spermatogenic disorders and testicular germ cell tumors. World J Urol 28:631-635
16. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13:5703-5709
17. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H (2006) Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 97:484-491
18. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T (2008) EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 122:595-602
19. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K, Ito H (2009) High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 45:39-46
20. Kamijima S, Tobe T, Suyama T, Ueda T, Igarashi T, Ichikawa T, Ito H (2005) The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. Int J Urol 12:941-947. doi: 10.1111/j.1442-2042.2005.01159.x
21. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24:268-273
22. Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA (2006) Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 12:1168-1174
23. Chowdhury GM, Kojima K, Kanayama H, Tsuji M, Kurokawa Y, Kagawa S (1996) The proliferation index of MIB-1 as a prognostic factor for patients with transitional cell carcinoma of the upper urinary tract. Cancer 78:827-833
24. Jeon HG, Jeong IG, Bae J, Lee JW, Won JK, Paik JH, Kim HH, Lee SE, Lee E (2010) Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma. Urology 76(513):e512-e517
25. Joung JY, Yang SO, Jeong IG, Han KS, Seo HK, Chung J, Park WS, Lee GK, Lee KH (2008) Identification of immunohistochemical factors that predict the synchronous or metachronous development of bladder tumors in patients with upper urinary tract tumors. Urol Int 81:306-311. doi: 10.1159/000151409
26. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629
27. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95:661-668
28. Mimori K, Ogawa K, Okamoto M, Sudo T, Inoue H, Mori M (2005) Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 31:376-380
29. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, Ponder BA, Nakamura Y, Hamamoto R (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102:1298-1305
30. Wagener N, Macher-Goeppinger S, Pritsch M, Husing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F, Hohenfellner M (2010) Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10:524
31. Wan L, Li X, Shen H, Bai X (2013) Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol 15:132-138
32. Weikert S, Christoph F, Kollermann J, Muller M, Schrader M, Miller K, Krause H (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16:349-353
33. Arisan S, Buyuktuncer ED, Palavan-Unsal N, Caskurlu T, Cakir OO, Ergenekon E (2005) Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 75:252-257
34. Hinz S, Kempkensteffen C, Christoph F, Hoffmann M, Krause H, Schrader M, Schostak M, Miller K, Weikert S (2008) Expression of the polycomb group protein EZH2 and its relation to outcome in patients with urothelial carcinoma of the bladder. J Cancer Res Clin Oncol 134:331-336
35. Wang H, Albadine R, Magheli A, Guzzo TJ, Ball MW, Hinz S, Schoenberg MP, Netto GJ, Gonzalgo ML (2012) Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder. Urol Oncol 30:428-433
36. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernandez MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, Shariat SF (2009) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612-618. doi: 10.1200/JCO.2008.17.2361
37. Xiao Y (2011) Enhancer of zeste homolog 2: a potential target for tumor therapy. Int J Biochem Cell Biol 43:474-477
38. Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A, Danesi R (2012) EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer Metastasis Rev 31:753-761
39. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492:108-112
40. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT (2007) EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 67:547-556
41. Chen Y, Lin MC, Yao H, Wang H, Zhang AQ, Yu J, Hui CK, Lau GK, He ML, Sung J, Kung HF (2007) Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46:200-208
42. Wagener N, Holland D, Bulkescher J, Crnkovic-Mertens I, Hoppe-Seyler K, Zentgraf H, Pritsch M, Buse S, Pfitzenmaier J, Haferkamp A, Hohenfellner M, Hoppe-Seyler F (2008) The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Int J Cancer 123:1545-1550
43. Holland D, Hoppe-Seyler K, Schuller B, Lohrey C, Maroldt J, Durst M, Hoppe-Seyler F (2008) Activation of the enhancer of zeste homologue 2 gene by the human papillomavirus E7 oncoprotein. Cancer Res 68:9964-9972
44. Zhang YB, Niu HT, Chang JW, Dong GL, Ma XB (2011) EZH2 silencing by RNA interference inhibits proliferation in bladder cancer cell lines. Eur J Cancer Care (Engl) 20:106-112
45. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, Hirai K, Teratani T, Namatame N, Yamamoto Y, Hanai K, Kato T, Sano A, Ochiya T (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A 102:12177-12182. doi: 10.1073/pnas.0501753102
46. Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K (2010) An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 16:286-294. doi: 10.1038/nm.2100
47. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B (2004) Focus on bladder cancer. Cancer Cell 6:111-116. doi: 10.1016/j.ccr.2004. 08.002